Cytokinetics Incorporated (CYTK)

Business: Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

IPO Date: 29-Apr-2004

CEO, Pres & Director: Mr. Robert I. Blum

Sr. VP & CFO: Mr. Ching W. Jaw

Listing: NASDAQ: CYTK

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.cytokinetics.com

Market cap: $4,965.16 Mln

Revenue (TTM): $62.27 Mln

Earnings (TTM): $-215.92 Mln

Cash: $586.03 Mln

Total Debt: $261.71 Mln

Insider's Holding: 4.45%

Liquidity: Low

52 Week range: $29.10 - 54.74

Shares outstanding: 85,652,200

10 Years Aggregate:

• CFO: $-471.59 Mln
• EBITDA: $-660.93 Mln
• Net Profit: $-808.16 Mln